(MRK) Merck - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 298.764m USD | Total Return: 45% in 12m

Stock Oncology, Vaccines, Antibiotics, Cardiovascular, Veterinary
Total Rating 77
Safety 93
Buy Signal 0.66
Drug Manufacturers - General +6.3
Pharmaceuticals -0.1
Market Cap: 298,764m
Avg Trading Vol: 983M USD
ATR: 2.34%
Peers RS (IBD): 60.1
Risk 5d forecast
Volatility28.5%
Rel. Tail Risk-10.4%
Reward TTM
Sharpe Ratio1.13
Alpha32.72
Character TTM
Beta0.193
Beta Downside0.085
Drawdowns 3y
Max DD43.44%
CAGR/Max DD0.15
EPS (Earnings per Share) EPS (Earnings per Share) of MRK over the last years for every Quarter: "2021-03": 1.4, "2021-06": 1.31, "2021-09": 1.75, "2021-12": 1.8, "2022-03": 2.14, "2022-06": 1.87, "2022-09": 1.85, "2022-12": 1.62, "2023-03": 1.4, "2023-06": -2.06, "2023-09": 2.13, "2023-12": 0.03, "2024-03": 2.07, "2024-06": 2.28, "2024-09": 1.57, "2024-12": 1.72, "2025-03": 2.22, "2025-06": 2.13, "2025-09": 2.58, "2025-12": 2.04,
EPS CAGR: -1.27%
EPS Trend: 20.7%
Last SUE: 0.42
Qual. Beats: 0
Revenue Revenue of MRK over the last years for every Quarter: 2021-03: 10627, 2021-06: 11402, 2021-09: 13154, 2021-12: 13521, 2022-03: 15901, 2022-06: 14593, 2022-09: 14959, 2022-12: 13830, 2023-03: 14487, 2023-06: 15035, 2023-09: 15962, 2023-12: 14630, 2024-03: 15775, 2024-06: 16112, 2024-09: 16657, 2024-12: 15624, 2025-03: 15529, 2025-06: 15806, 2025-09: 17276, 2025-12: 16400,
Rev. CAGR: 0.83%
Rev. Trend: 65.7%
Last SUE: 1.27
Qual. Beats: 1
Description: MRK Merck

Merck & Co., Inc. (NYSE: MRK) is a global healthcare leader that markets a broad portfolio of human pharmaceuticals-including flagship immuno-oncology drug Keytruda and diabetes treatments Januvia/Janumet-as well as a wide range of veterinary vaccines and companion-animal products. The company also leverages a network of collaborations, such as co-development deals with AstraZeneca on Lynparza and with Daiichi Sankyo on ADC candidates, to expand its pipeline across oncology and specialty therapeutics.

In its most recent fiscal year, Merck generated $59.3 billion in revenue, driven largely by Keytruda’s $15.5 billion sales run-rate, and reported earnings per share of $8.78. The firm maintained a dividend yield of roughly 2.9% and invested $9.4 billion in R&D, underscoring its commitment to pipeline growth. Recent FDA approvals for the COVID-19 vaccine Vaxneuvance and the oncology drug Delstrigo have further bolstered its product pipeline.

Sector-wide, the aging U.S. population and rising demand for immuno-oncology therapies continue to lift the pharmaceuticals industry, while consolidation among biotech firms creates partnership opportunities that Merck is well-positioned to capture. For a deeper dive into MRK’s valuation metrics, you might explore the analysis on ValueRay.

Headlines to Watch Out For
  • Keytruda sales growth drives oncology revenue expansion
  • Gardasil vaccine demand boosts prophylactic portfolio
  • Research and development pipeline success impacts future earnings
  • Generic drug competition threatens mature product sales
  • Regulatory approvals and setbacks influence drug market access
Piotroski VR‑10 (Strict) 6.0
Net Income: 18.25b TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA -6.42 > 1.0
NWC/Revenue: 23.36% < 20% (prev 16.15%; Δ 7.22% < -1%)
CFO/TA 0.12 > 3% & CFO 16.47b > Net Income 18.25b
Net Debt (35.97b) to EBITDA (26.31b): 1.37 < 3
Current Ratio: 1.54 > 1.5 & < 3
Outstanding Shares: last quarter (2.49b) vs 12m ago -2.09% < -2%
Gross Margin: 81.50% > 18% (prev 0.76%; Δ 8.07k% > 0.5%)
Asset Turnover: 51.20% > 50% (prev 54.79%; Δ -3.60% > 0%)
Interest Coverage Ratio: 16.23 > 6 (EBITDA TTM 26.31b / Interest Expense TTM 1.36b)
Altman Z'' 4.51
A: 0.11 (Total Current Assets 43.52b - Total Current Liabilities 28.33b) / Total Assets 136.87b
B: 0.53 (Retained Earnings 73.08b / Total Assets 136.87b)
C: 0.17 (EBIT TTM 22.01b / Avg Total Assets 126.99b)
D: 0.84 (Book Value of Equity 70.58b / Total Liabilities 84.20b)
Altman-Z'' Score: 4.51 = AA
Beneish M -2.86
DSRI: 1.22 (Receivables 12.68b/10.28b, Revenue 65.01b/64.17b)
GMI: 0.94 (GM 81.50% / 76.32%)
AQI: 1.04 (AQ_t 0.49 / AQ_t-1 0.47)
SGI: 1.01 (Revenue 65.01b / 64.17b)
TATA: 0.01 (NI 18.25b - CFO 16.47b) / TA 136.87b)
Beneish M-Score: -2.86 (Cap -4..+1) = A
What is the price of MRK shares? As of April 05, 2026, the stock is trading at USD 120.29 with a total of 10,712,163 shares traded.
Over the past week, the price has changed by +1.04%, over one month by +1.61%, over three months by +13.33% and over the past year by +44.99%.
Is MRK a buy, sell or hold? Merck has received a consensus analysts rating of 4.04. Therefore, it is recommended to buy MRK.
  • StrongBuy: 12
  • Buy: 3
  • Hold: 11
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MRK price?
Wallstreet Target Price 128.3 6.6%
Analysts Target Price 128.3 6.6%
MRK Fundamental Data Overview as of 03 April 2026
P/E Trailing = 16.6217
P/E Forward = 23.5294
P/S = 4.5956
P/B = 5.6793
P/EG = 3.6806
Revenue TTM = 65.01b USD
EBIT TTM = 22.01b USD
EBITDA TTM = 26.31b USD
Long Term Debt = 46.75b USD (from longTermDebt, last quarter)
Short Term Debt = 2.88b USD (from shortTermDebt, last quarter)
Debt = 50.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.97b USD (from netDebt column, last quarter)
Enterprise Value = 334.73b USD (298.76b + Debt 50.53b - CCE 14.56b)
Interest Coverage Ratio = 16.23 (Ebit TTM 22.01b / Interest Expense TTM 1.36b)
EV/FCF = 27.08x (Enterprise Value 334.73b / FCF TTM 12.36b)
FCF Yield = 3.69% (FCF TTM 12.36b / Enterprise Value 334.73b)
FCF Margin = 19.01% (FCF TTM 12.36b / Revenue TTM 65.01b)
Net Margin = 28.08% (Net Income TTM 18.25b / Revenue TTM 65.01b)
Gross Margin = 81.50% ((Revenue TTM 65.01b - Cost of Revenue TTM 12.03b) / Revenue TTM)
Gross Margin QoQ = 92.71% (prev 77.69%)
Tobins Q-Ratio = 2.45 (Enterprise Value 334.73b / Total Assets 136.87b)
Interest Expense / Debt = 0.81% (Interest Expense 411.0m / Debt 50.53b)
Taxrate = 13.39% (458.0m / 3.42b)
NOPAT = 19.06b (EBIT 22.01b * (1 - 13.39%))
Current Ratio = 1.54 (Total Current Assets 43.52b / Total Current Liabilities 28.33b)
Debt / Equity = 0.96 (Debt 50.53b / totalStockholderEquity, last quarter 52.61b)
Debt / EBITDA = 1.37 (Net Debt 35.97b / EBITDA 26.31b)
Debt / FCF = 2.91 (Net Debt 35.97b / FCF TTM 12.36b)
Total Stockholder Equity = 50.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.37% (Net Income 18.25b / Total Assets 136.87b)
RoE = 36.19% (Net Income TTM 18.25b / Total Stockholder Equity 50.45b)
RoCE = 22.65% (EBIT 22.01b / Capital Employed (Equity 50.45b + L.T.Debt 46.75b))
RoIC = 21.02% (NOPAT 19.06b / Invested Capital 90.69b)
WACC = 5.80% (E(298.76b)/V(349.30b) * Re(6.66%) + D(50.53b)/V(349.30b) * Rd(0.81%) * (1-Tc(0.13)))
Discount Rate = 6.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.30%
[DCF] Terminal Value 85.77% ; FCFF base≈14.65b ; Y1≈13.87b ; Y5≈13.19b
[DCF] Fair Price = 145.0 (EV 394.41b - Net Debt 35.97b = Equity 358.44b / Shares 2.47b; r=6.0% [WACC]; 5y FCF grow -6.93% → 3.0% )
EPS Correlation: 20.65 | EPS CAGR: -1.27% | SUE: 0.42 | # QB: 0
Revenue Correlation: 65.66 | Revenue CAGR: 0.83% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.93 | Chg7d=-0.011 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-12-31): EPS=5.12 | Chg7d=-0.002 | Chg30d=+0.004 | Revisions Net=+0 | Growth EPS=-42.9% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=9.77 | Chg7d=-0.026 | Chg30d=-0.013 | Revisions Net=-1 | Growth EPS=+90.5% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.9% (Discount Rate 7.9% - Earnings Yield 6.0%)
[Growth] Growth Spread = +1.8% (Analyst 3.7% - Implied 1.9%)
External Resources
Dataroma Stockcircle